|Bid||1.180 x 0|
|Ask||1.190 x 0|
|Day's range||1.1750 - 1.2250|
|52-week range||1.1750 - 2.4700|
|Beta (3Y monthly)||2.38|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb. 2019 - 4 Mar. 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.95|
NEW YORK and MELBOURNE, Australia, Nov. 26, 2018 -- Tasly Pharmaceutical Group and Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the first Joint Steering.
MELBOURNE, Australia and NEW YORK, Nov. 15, 2018 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported strong financial results and provided operational highlights for the.
NEW YORK and MELBOURNE, Australia, Nov. 15, 2018 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended September 30, 2018 in a.
NEW YORK and MELBOURNE, Australia, Nov. 11, 2018 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that results from a 159-patient randomized, sham-controlled Phase 2.
NEW YORK and MELBOURNE, Australia, Nov. 09, 2018 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will host a webcast to discuss the results of the Phase 2b trial evaluating its.
Nasdaq:MESO) today announced it has expanded its partnership with JCR Pharmaceuticals Co. Ltd. in Japan for wound healing in patients with Epidermolysis Bullosa (EB). JCR has received Orphan Designation for the allogeneic mesenchymal stem cell (MSC) product TEMCELL HS Inj1 in the treatment of EB. Based on promising results from an investigator-initiated trial in Japan, JCR intends to seek label extension for TEMCELL in Japan beyond its existing approval for the treatment of acute graft versus host disease.
Mesoblast has received US$40 million (AUD$57 million) from Tasly, comprising an upfront technology access fee of US$20 million and an equity purchase of US$20 million for which Mesoblast Limited has issued 14,464,259 fully paid ordinary shares to Tasly. As consideration, Tasly has received exclusive rights and will fund all development, manufacturing and commercialization activities in China for MPC-150-IM for the treatment and prevention of chronic heart failure and MPC-25-IC for the prevention and treatment of acute myocardial infarction.
NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial.
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Mesoblast Limited (ASX:MSB, Nasdaq:MESO) today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell (MPC) heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome (HLHS) was featured at the First Cardiac Regenerative Symposium for Congenital Heart Disease in Baltimore, Maryland on the weekend. A randomized, placebo-controlled 24-patient trial is ongoing at Boston Children’s Hospital and combines an injection of MPC-150-IM into the left ventricle with corrective heart surgery in children under the age of five with HLHS.
NEW YORK and MELBOURNE, Australia, Sept. 20, 2018-- Mesoblast Limited today announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease ...
Mesoblast Limited’s (ASX:MSB): Mesoblast Limited develops cell-based medicines. With the latest financial year loss of -US$76.8m and a trailing-twelve month of -US$41.6m, the AU$750.5m market-cap alleviates its loss by movingRead More...